Suchergebnisse - "Allweiss, Lena"

PubPharm (64)

1

Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers

enthalten in: PLoS computational biology | 2024

von Kitagawa, K. | Kim, K. | Iwamoto, M. | +13

UpdateOf: bioRxiv. 2023 Jun 07;:. - PMID 37333409

2

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

enthalten in: Journal of hepatology | 2024

von Allweiss, L. | Volmari, A. | Suri, V. | +9

3

Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation for analyzing extracellular viral markers

enthalten in: bioRxiv.org | 2023

von Kitagawa, K. | Kim, K. | Iwamoto, M. | +13

4

Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation for analyzing extracellular viral markers

enthalten in: bioRxiv : the preprint server for biology | 2023

von Kitagawa, K. | Kim, K. | Iwamoto, M. | +13

UpdateIn: PLoS Comput Biol. 2024 Mar 11;20(3):e1011238. - PMID 38466770

5

Quantification of the hepatitis B virus cccDNA : evidence-based guidelines for monitoring the key obstacle of HBV cure

enthalten in: Gut | 2023

von Allweiss, L. | Testoni, B. | Yu, M. | +11

6

Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment

enthalten in: JHEP reports : innovation in hepatology | 2023

von Giersch, K. | Perez-Gonzalez, P. | Hendricks, L. | +11

7

A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics

enthalten in: Journal of hepatology | 2023

von Anolli, M. | Degasperi, E. | Allweiss, L. | +8

8

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202) : a multicentre, randomised, parallel-group, open-label, phase 2 trial

enthalten in: The lancet / Infectious diseases | September 13, 2022

von Wedemeyer, H. | Schöneweis, K. | Bogomolov, P. | +26

9

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202) : a multicentre, randomised, parallel-group, open-label, phase 2 trial

enthalten in: The Lancet. Infectious diseases | 2023

von Wedemeyer, H. | Schöneweis, K. | Bogomolov, P. | +26

CommentIn: Lancet Infect Dis. 2023 Jan;23(1):14-16. - PMID 36113539

10

Prediction of elimination of intrahepatic cccDNA in hepatitis B virus-infected patients by a combination of noninvasive viral markers

enthalten in: bioRxiv.org | 2022

von Kim, K. | Iwamoto, M. | Kitagawa, K. | +20

1
2
3
4
5
6
7
Nächster »
[7]